An in silico transwell device for the study of drug transport and drug-drug interactions

被引:14
|
作者
Garmire, Lana X.
Garmire, David G.
Hunt, C. Anthony
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, BioSyst Grp, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Biopharmaceut Sci, UCB Joint Grad Grp Bioengn, San Francisco, CA 94143 USA
[3] Univ Calif Berkeley, Grad Grp Comparat Biochem, Berkeley, CA 94720 USA
[4] Univ Calif Berkeley, Berkeley Sensor & Actuator Ctr, Berkeley, CA 94720 USA
关键词
agent-based modeling; discrete event; drug transport; drug-drug interaction; emergent properties; simulation;
D O I
10.1007/s11095-007-9391-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. Methods. We used the synthetic modeling method. Specialized software components represented spatial and functional features including cell components, semi-porous tight junctions, and metabolizing enzymes. Mobile components represented drugs. Experiments were conducted and analyzed as done in vitro. Results. Verification experiments provided data analogous to those in the literature. ISTD parameters were tuned to simulate and match in vitro urea transport data; the objects representing tight junction (effective radius of 6.66 angstrom) occupied 0.066% of the surface area. That ISTD was then tuned to simulate pH-dependent, in vitro alfentanil transport properties. The resulting ISTD predicted the passive transport properties of 14 additional compounds, individually and all together in one in silico experiment. The function of a two-site enzymatic component was cross-validated with a kinetic model and then experimentally validated against in vitro benzyloxyresorufin metabolism data. Those components were used to exemplify drug-drug interaction studies. Conclusions. The ISTD is an example of a new class of simulation models capable of realistically representing complex drug transport and drug-drug interaction phenomena.
引用
收藏
页码:2171 / 2186
页数:16
相关论文
共 50 条
  • [31] Drug-drug interactions with raltegravir
    Burger D.M.
    European Journal of Medical Research, 14 (Suppl 3) : 17 - 21
  • [32] DRUG-DRUG INTERACTIONS AS AN ISSUE IN DRUG DEVELOPMENT
    Jochemsen, R.
    Bouzom, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 2 - 2
  • [33] DRUG UTILIZATION AND POTENTIAL DRUG-DRUG INTERACTIONS
    LAVENTURIER, MF
    TALLEY, RB
    HEFNER, DL
    KENNARD, LH
    JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1976, 16 (02): : 77 - 81
  • [34] Adverse drug reactions related to drug-drug interactions: lower severity level of drug-drug interactions and pharmacodynamic interactions are oversighted
    Kheloufi, F.
    Duval, M.
    Rouby, F.
    Ponte, J.
    Blin, O.
    Default, A.
    Micallef, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 89 - 89
  • [35] Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches
    Peng, Yaru
    Cheng, Zeneng
    Xie, Feifan
    METABOLITES, 2021, 11 (02) : 1 - 16
  • [36] Pharmacokinetic Drug-Drug Interactions and Herb-Drug Interactions
    Choi, Min-Koo
    Song, Im-Sook
    PHARMACEUTICS, 2021, 13 (05)
  • [37] Drug-drug interactions: is there an optimal way to study them?
    Lewis, L. D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (06) : 781 - 783
  • [38] Observational study of drug-drug interactions in oncological inpatients
    Sacramento Diaz-Carrasco, Maria
    Almanchel-Rivadeneyra, Miguel
    Tomas-Luiz, Aina
    Pelegrin-Montesinos, Sandra
    Ramirez-Roig, Cristina
    Jose Fernandez-Avila, Juan
    FARMACIA HOSPITALARIA, 2018, 42 (01) : 10 - 15
  • [39] DRUG-DRUG INTERACTION DATABASES: SENSITIVITY AND SPECIFICITY TO DETECT MANIFEST DRUG-DRUG INTERACTIONS, RELIABILITY RATINGS AND MANAGEMENT STRATEGIES OF POTENTIAL DRUG-DRUG INTERACTIONS
    Ocovska, Z.
    Marikova, M.
    Kukralova, K.
    Vlcek, J.
    VALUE IN HEALTH, 2022, 25 (01) : S140 - S141
  • [40] Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments
    Fokter, Nina
    Mozina, Martin
    Brvar, Miran
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (3-4) : 81 - 88